UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2024 P 1464-1
Program	Prior Authorization/Notification
Medication	Yorvipath® (palopegteriparatide)
P&T Approval Date	12/2024
Effective Date	3/1/2025

1. Background:

Yorvipath® is a parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults.

Limitations of Use:
- Yorvipath was not studied for acute post-surgical hypoparathyroidism.
- Titration scheme was only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment.

2. Coverage Criteria[a]:

A. **Initial Authorization**

1. **Yorvipath** will be approved based on **all** of the following criteria:

    a. Diagnosis of hypoparathyroidism

    -AND-

    b. Yorvipath is not being used to treat *acute* post-surgical hypoparathyroidism

    -AND-

    c. Patient has achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D (e.g., calcitriol) treatment

    Authorization will be issued for 12 months

B. **Reauthorization**

1. **Yorvipath** will be approved based on the following criterion:

    a. Documentation of positive clinical response to Yorvipath therapy

    Authorization will be issued for 12 months

[a] State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization

© 2024 UnitedHealthcare Services, Inc.

management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Medical Necessity may be in place

4. References:

1. Yorvipath® [package insert]. Princeton, NJ: Ascendis Pharma, Inc.; August 2024.

Program	Prior Authorization/Notification - Yorvipath (palopegteriparatide)
Change Control	
12/2024	New program.

© 2024 UnitedHealthcare Services, Inc.